Summary
Eli Lilly & Company's 2017 10-K filing reveals a year marked by significant revenue growth, primarily driven by strong performance in its human pharmaceutical segment, particularly with key products like Trulicity and Jardiance. However, the company also faced substantial charges in 2017, including a large provision for income taxes due to the Tax Cuts and Jobs Act of 2017, and significant asset impairment, restructuring, and other special charges, primarily related to cost-reduction efforts and early retirement programs. These factors resulted in a net loss for the year. Despite the net loss, the company continued its commitment to shareholders through dividends and share repurchases, and is actively managing its late-stage pipeline with new molecular entities under development. Investors should note the company's ongoing efforts to address patent expirations and generic competition for several key products, alongside the strategic review of its Elanco Animal Health segment, which could lead to significant corporate changes.
Financial Highlights
53 data points| Revenue | $19.97B |
| Cost of Revenue | $6.07B |
| Gross Profit | $13.90B |
| R&D Expenses | $5.10B |
| SG&A Expenses | $5.98B |
| Interest Expense | $225.00M |
| Net Income | -$204.10M |
| EPS (Basic) | $-0.19 |
| EPS (Diluted) | $-0.19 |
| Shares Outstanding (Basic) | 1.05B |
| Shares Outstanding (Diluted) | 1.05B |
Key Highlights
- 1Revenue increased by 8% to $22.87 billion in 2017, driven by strong growth in human pharmaceuticals, particularly Trulicity (+119%) and Jardiance (+122%).
- 2The company reported a net loss of $204.1 million ($0.19 per share) in 2017, a significant reversal from a net income of $2.74 billion in 2016, primarily due to a $1.91 billion provisional tax charge related to the 2017 Tax Act.
- 3Significant restructuring and special charges of $1.67 billion were incurred in 2017, including costs related to a U.S. voluntary early retirement program and asset impairments.
- 4Patent expirations and generic competition are noted as significant challenges, particularly for Cialis, Alimta, and Strattera, leading to revenue declines in these products.
- 5Eli Lilly is actively managing its product pipeline with approximately 40 potential new drugs in human testing or under regulatory review, including promising candidates for Alzheimer's disease, cancer, and diabetes.
- 6The company is reviewing strategic alternatives for its Elanco Animal Health segment, with an update expected by mid-2018.
- 7Despite the net loss, the company maintained its commitment to shareholders by increasing its quarterly dividend and continuing its share repurchase program.